#1 Clinical Trials Search in Europe

Study on the Effectiveness of Dermatophagoides Allergen Extracts and Histamine Dihydrochloride for Patients with Allergies

2 1 1

What is this study about?

This clinical trial is focused on studying allergies caused by dust mites, specifically Dermatophagoides pteronyssinus and Dermatophagoides farinae. The trial aims to standardize the biological response to allergenic extracts from these mites. The treatment involves a solution for skin-prick tests, which is a method used to identify allergic reactions by introducing small amounts of allergens into the skin. The substances used in this study include histamine dihydrochloride, which serves as a positive control, and sodium chloride, used as a negative control. The main goal is to understand how different concentrations of these allergenic extracts affect the skin’s reaction.

Participants in the study will undergo skin-prick tests where small amounts of the allergenic extracts are applied to the skin. The reaction is measured by the size of the wheal, which is a small, raised area on the skin. This helps in determining the dose-response relationship, which is how the skin reacts to different concentrations of the allergen. The study will also assess the safety of these extracts by monitoring any adverse reactions that may occur during the testing process.

The trial is designed to provide valuable information on the effectiveness and safety of these allergenic extracts, which could help in better managing allergies related to dust mites. The study is expected to run until April 2025, with recruitment starting in January 2025. Participants will be selected based on specific criteria, including a confirmed allergy to the dust mites being studied. The results of this trial could lead to improved treatments for individuals suffering from dust mite allergies.

1 initial assessment

The trial begins with an initial assessment to confirm eligibility. This includes a skin prick test to check for allergies to Dermatophagoides pteronyssinus and Dermatophagoides farinae. A positive result is indicated by a wheal diameter of at least 3 mm larger than the negative control.

A positive control test is also conducted using a solution of histamine dihydrochloride at 10 mg/ml, which should produce a wheal diameter of at least 4 mm.

2 administration of allergen extracts

The patient receives a series of skin prick tests using solutions containing extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae. These solutions are administered intradermally, which means they are injected into the skin.

The purpose is to measure the area of the wheal that forms on the skin, which helps in determining the dose-response relationship.

3 monitoring and data collection

The size of the wheal is measured in square millimeters to calculate the primary endpoint. This involves estimating the dose-response relationship and determining the concentration of extract that produces a wheal equivalent to that produced by the histamine solution.

Safety is assessed by monitoring for any adverse reactions during the study.

4 completion of trial

The trial is expected to conclude by April 15, 2025. Data collected will be analyzed to achieve the main objective of biological standardization of the allergenic extracts.

Who Can Join the Study?

  • The patient must live in an area where the dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae are common. These are tiny creatures that can cause allergies, often found in humid and mild climates like the Mediterranean coast.
  • The patient should be between 18 and 50 years old, and it doesn’t matter if they are male or female.
  • The patient must have an allergy to the dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae that is confirmed by two tests:
    • A skin prick test showing a reaction at least 3 mm larger than the negative control. This test involves placing a small amount of allergen on the skin and pricking it to see if there is a reaction.
    • A positive result on a specific IgE test, which is a blood test that checks for allergy-related antibodies, showing a class 1 or higher result.
  • The patient must have a skin reaction of at least 4 mm when tested with a solution of histamine dihydrochloride, which is used as a positive control to ensure the skin reacts properly.
  • The patient must understand the study’s purpose and agree to participate by signing an informed consent form, which is a document explaining the study in detail.

Who Cannot Join the Study?

  • Individuals with known allergies to the substances being tested cannot participate. Allergies are when your body reacts negatively to certain things, like foods or pollen.
  • Children under the age of 3 are not allowed to join the study.
  • People who are part of a vulnerable group, which means they might need extra care or protection, are not included in the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hospital General Universitario De Castellon Castello De La Plana Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
15.01.2025

Trial locations

Investigated drugs:

Dermatophagoides pteronyssinus allergen extract is used in the trial to help standardize the biological response to allergens from this specific type of dust mite. This extract is designed to test and measure how the body reacts to the allergens, which can help in understanding and managing allergic reactions.

Dermatophagoides farinae allergen extract is another component of the trial, similar to the Dermatophagoides pteronyssinus extract. It is used to evaluate the body’s response to allergens from a different type of dust mite. This helps in comparing and standardizing the biological effects of different dust mite allergens.

Investigated diseases:

Allergies – Allergies occur when the immune system reacts to a foreign substance, such as pollen, pet dander, or certain foods, that doesn’t cause a reaction in most people. The immune system produces antibodies that identify a particular allergen as harmful, even though it isn’t. This reaction can lead to symptoms such as sneezing, itching, a runny nose, or hives. In some cases, exposure to an allergen can cause a more severe reaction, known as anaphylaxis. Allergies can develop at any age and can change over time. The severity of allergies varies from person to person and can range from minor irritation to more significant discomfort.

Trial ID:
2024-514108-15-01
Protocol code:
API-EAD-2024-01
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A Study Testing Prolonged versus Single Dose Penicillin Challenge in Patients with Suspected Penicillin Allergy Using Amoxicillin

    Recruiting

    3 1
    Investigated drugs:
    Belgium Denmark

  • Standardization of Olea europaea pollen extract for patients with olive pollen allergies

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain